{"log_id": 5271691466540959494, "direction": 0, "words_result_num": 37, "words_result": [{"probability": {"variance": 0.003876, "average": 0.98778, "min": 0.596047}, "location": {"width": 816, "top": 138, "height": 50, "left": 192}, "words": "发生率与安慰剂组相似,低于1%大于0.5%的不良事件有:胸痛、乏力、疼痛、外周性生"}, {"probability": {"variance": 5e-06, "average": 0.999162, "min": 0.989417}, "location": {"width": 860, "top": 188, "height": 50, "left": 150}, "words": "水肿、眩晕、腹痛、消化不良、肠胃炎、恶心、心动过速、高胆固醇血症、高脂血症、高尿"}, {"probability": {"variance": 3e-06, "average": 0.999031, "min": 0.991729}, "location": {"width": 861, "top": 236, "height": 54, "left": 150}, "words": "酸血症、关节疼痛、关节炎、肌肉疼痛、骨骼疼痛、皮疹和面部水肿等。上述不良事件是否"}, {"probability": {"variance": 4e-06, "average": 0.998197, "min": 0.993771}, "location": {"width": 239, "top": 302, "height": 36, "left": 153}, "words": "与服用本品有关尚不明确"}, {"probability": {"variance": 1e-05, "average": 0.998691, "min": 0.98523}, "location": {"width": 814, "top": 336, "height": 49, "left": 196}, "words": "实验室检查结果:在临床对照试验中,具有重要临床意义的实验室参数的变化与奥美沙"}, {"probability": {"variance": 2e-06, "average": 0.998058, "min": 0.995633}, "location": {"width": 198, "top": 401, "height": 35, "left": 151}, "words": "坦酯极少具有相关性"}, {"probability": {"variance": 0, "average": 0.999576, "min": 0.997116}, "location": {"width": 814, "top": 433, "height": 50, "left": 199}, "words": "血红蛋白和血细胞比容:偶见血红蛋白和血细胞比容略有下降(分别平均下降了大约"}, {"probability": {"variance": 3.5e-05, "average": 0.993062, "min": 0.977479}, "location": {"width": 258, "top": 497, "height": 37, "left": 152}, "words": "03g/dL和0.3体积百分比)"}, {"probability": {"variance": 2.9e-05, "average": 0.997675, "min": 0.978923}, "location": {"width": 657, "top": 535, "height": 46, "left": 197}, "words": "肝功能检查:偶见肝脏酶上升和或血胆红素上升,但会自行恢复正常"}, {"probability": {"variance": 0.001496, "average": 0.981583, "min": 0.887208}, "location": {"width": 150, "top": 600, "height": 27, "left": 198}, "words": "2.上市后经验"}, {"probability": {"variance": 4e-06, "average": 0.999156, "min": 0.988787}, "location": {"width": 801, "top": 630, "height": 49, "left": 200}, "words": "以下为上市后报告的不良反应。因这些不良反应来自于人数不确定的患者的自发报告"}, {"probability": {"variance": 3e-06, "average": 0.999252, "min": 0.991435}, "location": {"width": 502, "top": 685, "height": 46, "left": 157}, "words": "通常并不能确切评估其发生率以及与药物的因果关系"}, {"probability": {"variance": 5e-06, "average": 0.998743, "min": 0.990128}, "location": {"width": 348, "top": 738, "height": 40, "left": 203}, "words": "全身:乏力、血管性水肿、过敏性反"}, {"probability": {"variance": 0.007117, "average": 0.914765, "min": 0.830401}, "location": {"width": 111, "top": 751, "height": 56, "left": 535}, "words": "有限"}, {"probability": {"variance": 0.000186, "average": 0.993948, "min": 0.94695}, "location": {"width": 303, "top": 791, "height": 34, "left": 202}, "words": "胃肠道:呕吐、口炎性腹泻样肠"}, {"probability": {"variance": 0, "average": 0.790021, "min": 0.790021}, "location": {"width": 35, "top": 790, "height": 31, "left": 635}, "words": "令"}, {"probability": {"variance": 8e-06, "average": 0.997994, "min": 0.991604}, "location": {"width": 264, "top": 840, "height": 37, "left": 203}, "words": "代谢和营养系统:高钾血症"}, {"probability": {"variance": 0.000142, "average": 0.993963, "min": 0.956582}, "location": {"width": 285, "top": 889, "height": 36, "left": 204}, "words": "肌肉骨骼系统:横纹肌溶解症"}, {"probability": {"variance": 0.019596, "average": 0.941837, "min": 0.449556}, "location": {"width": 400, "top": 928, "height": 50, "left": 204}, "words": "泌尿生殖系统:急性肾衰竭、血肌西决高"}, {"probability": {"variance": 3e-06, "average": 0.99918, "min": 0.993298}, "location": {"width": 373, "top": 982, "height": 41, "left": 207}, "words": "皮肤与附属器官:脱发、瘙痒、荨麻疹"}, {"probability": {"variance": 0.000305, "average": 0.996029, "min": 0.892631}, "location": {"width": 791, "top": 1010, "height": 55, "left": 232}, "words": "项对照试验和流行病学研究数据提示,高剂量奥美沙坦给药可能会增加糖尿病患者心"}, {"probability": {"variance": 3.6e-05, "average": 0.997353, "min": 0.972361}, "location": {"width": 860, "top": 1046, "height": 57, "left": 165}, "words": "血管(CV)的风险,但总体数据尚不确定。一项随机、安慰剂对照、双盲 ROADMAP研究"}, {"probability": {"variance": 0.008402, "average": 0.969465, "min": 0.42951}, "location": {"width": 846, "top": 1082, "height": 57, "left": 173}, "words": "(奥美沙坦与糖尿病微量白蛋白尿预防随机试验,n44),评价奥美沙坦40mg/日vs"}, {"probability": {"variance": 7.5e-05, "average": 0.997272, "min": 0.953604}, "location": {"width": 849, "top": 1118, "height": 57, "left": 167}, "words": "安慰剂用于2型糖尿病、正常白蛋白尿以及具有至少1项其他CV疾病风险因素的患者("}, {"probability": {"variance": 0.003376, "average": 0.989562, "min": 0.626975}, "location": {"width": 859, "top": 1153, "height": 58, "left": 169}, "words": "或不伴高血压)。该研究实现了其主要终点,即延迟微量白蛋白尿发作时间,但奥美沙坦对"}, {"probability": {"variance": 0.000742, "average": 0.99226, "min": 0.839612}, "location": {"width": 861, "top": 1189, "height": 58, "left": 167}, "words": "降低肾小球滤过率(GFR)方面无获益。结果显示,奥美沙坦组CV死亡率(特指突发性心"}, {"probability": {"variance": 1e-06, "average": 0.999245, "min": 0.994725}, "location": {"width": 861, "top": 1225, "height": 58, "left": 168}, "words": "源性死亡、致死性心肌梗死、致死性卒中、血运重建死亡)高于安慰剂组(奥美沙坦组15"}, {"probability": {"variance": 0.006264, "average": 0.968838, "min": 0.679273}, "location": {"width": 863, "top": 1260, "height": 60, "left": 167}, "words": "例vs.安慰剂组3例,HR4.9,95%置信区间[C1.4,17),但奥美沙坦组非致死性心肌梗"}, {"probability": {"variance": 0.011318, "average": 0.966617, "min": 0.557411}, "location": {"width": 433, "top": 1312, "height": 42, "left": 171}, "words": "死风险较低(HR0.64,95%C10.35,1.18)"}, {"probability": {"variance": 0.00374, "average": 0.987535, "min": 0.602923}, "location": {"width": 817, "top": 1332, "height": 57, "left": 214}, "words": "流行病学研究纳入65岁及65岁以上患者,总暴露量>300,00患者年。接受高剂量奥"}, {"probability": {"variance": 0.001849, "average": 0.989364, "min": 0.718554}, "location": {"width": 861, "top": 1367, "height": 61, "left": 172}, "words": "美沙坦(40mg/d)长达>6个月的亚组糖尿病患者发生死亡的风险高于接受其他血管紧张素"}, {"probability": {"variance": 0.004333, "average": 0.979, "min": 0.650489}, "location": {"width": 859, "top": 1404, "height": 60, "left": 175}, "words": "受体阻滞剂的糖尿病患者(HR2.0,95%Cl1.1,3.8)。相反,高剂量奥美沙坦组非糖尿病"}, {"probability": {"variance": 2.3e-05, "average": 0.997397, "min": 0.977779}, "location": {"width": 860, "top": 1440, "height": 59, "left": 173}, "words": "患者发生死亡的风险低于接受其他血管紧张素受体阻滞剂的非糖尿病患者(HR0.46,95%"}, {"probability": {"variance": 0.006467, "average": 0.981085, "min": 0.461307}, "location": {"width": 857, "top": 1476, "height": 60, "left": 177}, "words": "C|0.24,0.86)。低剂量奥美沙坦组患者与接受其他血管紧张素受体阻滞剂或接受治疗<6"}, {"probability": {"variance": 7e-06, "average": 0.998327, "min": 0.990404}, "location": {"width": 240, "top": 1534, "height": 37, "left": 179}, "words": "个月的患者之间未见差异"}, {"probability": {"variance": 7e-05, "average": 0.997817, "min": 0.949309}, "location": {"width": 817, "top": 1554, "height": 58, "left": 220}, "words": "总之,上述数据引起了对糖尿病患者使用高剂量奥美沙坦可能导致CV风险升高的关"}, {"probability": {"variance": 0.008552, "average": 0.963071, "min": 0.718455}, "location": {"width": 132, "top": 1598, "height": 25, "left": 543}, "words": "第3页/共10页"}], "language": 3}